We report a very uncommon case of a primary, non-metastatic gastrointestinal stromal tumor (GIST) arising in the prostate gland in a 60-year-old patient. The morphology and immunohistochemical profile of the disease resembled GIST of gastrointestinal origin, and the molecular driver of this malignancy was a double mutation in exons 11 and 13 of the KIT gene. The tumor was proliferating slowly, did respond to neoadjuvant therapy with the KIT-inhibiting agent imatinib and was cured by radical, retro-pubic prostatectomy followed by adjuvant imatinib treatment. We postulate that primary GIST tumors of the prostate can arise from Case
Introduction
Primary prostatic gastrointestinal stromal tumor (GIST) is an extremely rare entity with only a few cases reported in the world literature. While the vast majority of GIST originate from the gastrointestinal tract, GIST arising from extra-intestinal sites are very uncommon, and usually occur in anatomical localizations in close proximity to gastrointestinal structures, e.g. retroperitoneal, mesenteric or omental cases. In individual patients, rectal GIST can involve the prostate gland and mimic a primary prostate tumor. What we report here is a patient with a primary prostatic GIST without involvement of gastrointestinal structures.
Case Report
We describe the case of a 60-year-old male who presented in a regional hospital in 2009 with sporadic pollakisuria caused by a mass in the prostate gland of 12 cm in diameter. Figure  1 illustrates the radiological appearance of the tumour on pelvic computed tomography (CT). After initial watchful waiting until 2011 the patient underwent a biopsy of the prostate. Pathologic examination showed a mesenchymal tumor composed of spindle-shaped cells. On immunohistochemistry the tumor was positive for smooth muscle actin, CD34 and CD117 (KIT). Ki67 staining indicated a very low proliferation index of only 1%. Mutational analysis of tumor tissue revealed a heterozygous, double mutation of KIT in exon 11 p.Gly565Arg (c. GGA>AGA) and in exon 13 p.Lys642Glu (c.1924A>G), most likely arising as a consequence of multiple mutagenic hits [1, 2] .
The treating physicians decided to follow the patient without specific intervention, as he was almost asymptomatic and the disease appeared pretty stable over time. In 2015 he was transferred to the Department of General Medical Oncology at the University Hospitals in Leuven (Leuven, Belgium) for a second medical opinion and potential treatment.
The patient, a police officer who retired in 2014, had a general medical history of a sick sinus syndrome associated with paroxysmal arrhythmia, atrial flutter and tachycardia, thrombosis of the subclavian vein and a surgical history of vasectomy, implantation of a pacemaker and meniscus surgery. He had no relevant risk factors for malignancies and an unremarkable family history. He was in excellent condition when first presenting in our tertiary care clinic, was completely asymptomatic except for some mild dysuria/pollakisuria, and very reluctant to consider any active surgical treatment for the prostatic mass, given the fact that the tumor and the related symptoms had remained clinically stable over a period of 5 years.
The patient agreed though with staging procedures and a second transrectal biopsy to confirm the uncommon diagnosis. (18F)-fluorodeoxyglucose positron emission tomographycomputed tomography (PET CT) showed the presence of a metabolically active mass in the prostate gland, which had increased over time to 14 cm in diameter. The scan excluded the presence of another gastrointestinal or extra-gastrointestinal primary tumor or distant metastasis. The additional biopsy confirmed the working hypothesis of a low grade GIST arising in the prostate without major mitotic activity or spontaneous necrosis. Figure 2a shows the morphology of the tumor prior to any therapeutic intervention. Immunohistochemically the tissue stained positive for smooth muscle antigen, CD34, CD117 and Discovered on GIST 1 (DOG1) [3, 4] . Figure 2b illustrates the staining characteristics of the lesion.
Given the considerable size and documented slow progression of the primary tumor and the reluctance of the patient to undergo immediate primary surgery we strongly recommended to start systemic neoadjuvant treatment with imatinib, in analogy with our routine approach in patients with advanced rectal or esophageal GIST. With some delay the patient finally agreed in 01-2016 to start the tyrosine kinase inhibitor imatinib 400 mg per day. His compliance was good and he tolerated the oral treatment very well. Adverse events were limited to episodic muscle cramps in the lower extremities and intermittent hypophosphatemia as classical side effects of imatinib. An early reassessment of the disease with PET CT within 4 weeks after the start of treatment showed an excellent partial metabolic response of the primary tumor and confirmed again the absence of distant metastases. Figures 3b and c illustrate the radiological and metabolic response.
During further neoadjuvant treatment, his episodes of pollakisuria decreased in frequency and severity and he had excellent quality of life. In 04-2017 the primary tumor had shrunk to 9 cm in diameter on PET CT, with almost no residual (18F)-fluorodeoxyglucose uptake. In preparation of the resection of the tumor after neoadjuvant treatment a magnetic resonance tomography scan (MRT) of the pelvis was requested by the surgeons. This was performed in 11-2017 after replacing the patient's cardiac pacemaker by an MRT-compatible device. The MRT showed that the tumor was clearly confined to the prostate and had no anatomical relationship with the rectum or other intestinal structures.
In 12-2017 the patient underwent a radical retro-pubic prostatectomy performed by the urologist. Histology finally confirmed the diagnosis of a GIST of 7.3 cm in diameter after neoadjuvant treatment, located in the right lobe of the prostate, CD117 and DOG1 immunopositive. There was clear evidence of antitumoral effects of the preoperative therapy with imatinib but there was still presence of residual foci of vital tumor cells, which is a typical finding after neoadjuvant use of imatinib also in GIST arising in the gastrointestinal tract. Figure 2c shows the morphology of the tumor after imatinib treatment. As illustrated in Figure 4 , mutational analysis was repeated, confirming the presence of the KIT exon 13 mutation c.1924A>G (p.Lys642Glu); the exon 11 mutation could not be detected anymore, which may be explained by differential effects of the kinase inhibitor on tumor cells with different driver mutations and higher sensitivity of the exon 11 mutation to imatinib.
After surgery the patient re-initiated treatment with imatinib at a dose of 400 mg per day, which he is currently continuing until 01-2019 for a total perioperative treatment duration of 3 years, which is in line with current routine duration of adjuvant treatment in typical high risk gastrointestinal GIST. The patient is tolerating the postoperative treatment with imatinib even better than the neoadjuvant treatment, with no adverse events and no disease-specific complaints.
Results
At present, the patient is asymptomatic and tumor-free without any clinical or radiological evidence for residual disease.
Discussion/Conclusion
GISTs are the most common mesenchymal malignancies in some geographic regions [5] , and the most frequently encountered primary sarcoma arising in the gastrointestinal tract [6] . GIST tumors occurring outside of the gastrointestinal tract are extremely rare [7] . Primary GIST arising in the prostate have been reported in only a few cases [8] [9] [10] [11] [12] [13] [14] .
The morphological, immunohistochemical and mutational features of the tumor described in this case report match the diagnosis of a GIST. A primary rectal origin of the disease could be ruled out both by extensive imaging studies and macroscopically during surgery. The clinical, radiological and metabolic sensitivity of the tumor to the KIT-directed tyrosine kinase inhibitor imatinib resembles the response pattern of classical gastrointestinal primary GISTs to this highly efficient and usually well-tolerated treatment. With the exception of the anatomical localization of the primary tumor, all features of this disease meet the diagnostic criteria of GIST.
How in theory can GIST arise in the prostate? The major function of the organ is to propel its secretions into the seminal fluids upon ejaculation, but the prostate in man and rodents also displays spontaneous electrical signals that trigger non-propelling contractile activity [15] . Specific prostatic interstitial cells are believed to be involved in processes involving contractility of smooth muscle fibers within the organ and to be responsible for the generation of the spontaneous tone in the prostate [16] . Electron microscopic studies in rodent prostates have established that numerous interstitial cells lay between the epithelium and muscle layer, and between and within the muscle bundles. These prostatic interstitial cells display surprising microstructural similarity with the interstitial cells of Cajal, the pacemaker cells in the gastrointestinal tract [17] . Furthermore, both the interstitial cells of Cajal in the bowel wall and the prostatic interstitial cells can be labelled with antibodies directed against the KIT receptor (CD117).
According to the literature, typical GISTs of the gastrointestinal tract are believed to share a common progenitor with the interstitial cells of Cajal, or even arise directly from these cells. Our working hypothesis, based on the case presented here, is that in rare instances GIST can also arise from prostatic interstitial cells, which in turn likely belong to the same superfamily as other interstitial pacemakers in the gastrointestinal and urogenital tract and possibly in other organ systems with contractility as a physiological function. Under mutagenic stress these cells can give rise to diseases with similar, if not identical phenotype, genotype and biological behavior as classical GIST of the intestine. 
